First and only minimally invasive, transcatheter treatment approved for premature babies with a patent ductus, a life-threatening opening in their heart.
$10.1 Billion ($20.9B total)
KEY EXECUTIVES:
Miles D. White, Chairman and CEO
Brian J. Blaser, Exec. VP, Diagnostics Products
Robert B. Ford, Exec. VP, Medical Devices
Michael T. Rousseau, President, Cardiovascular and Neuromodulation
Br…
As MPO readers are certainly aware, Abbott Laboratories has been quite active in the M&A department this year. Following the string of medtech industry consolidation efforts—which shows absolutely no signs of slowing—Abbott purchased…